0 294

Cited 12 times in

Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.

Authors
 Hyeyoung Wang  ;  Sungwoo Ahn  ;  Sunghyun Kim  ;  Sunyoung Park  ;  Sangjung Park  ;  Hyunju Han  ;  Joo Hyuk Sohn  ;  SeungIl Kim  ;  Hyeyoung Lee 
Citation
 EXPERIMENTAL AND MOLECULAR PATHOLOGY, Vol.97(3) : 445-452, 2014 
Journal Title
 EXPERIMENTAL AND MOLECULAR PATHOLOGY 
ISSN
 0014-4800 
Issue Date
2014
MeSH
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/blood* ; Breast Neoplasms/blood ; Breast Neoplasms/pathology* ; Breast Neoplasms/therapy ; Female ; Humans ; Mastectomy ; Middle Aged ; Neoplastic Cells, Circulating*/drug effects ; Neoplastic Cells, Circulating*/pathology ; Real-Time Polymerase Chain Reaction/methods* ; Reverse Transcriptase Polymerase Chain Reaction
Keywords
Anti-tumor treatment ; Breast cancer ; Circulating tumor cells (CTCs) ; Molecular diagnosis ; Quantitative real-time PCR (RT-qPCR)
Abstract
Circulating tumor cells (CTCs) are an independent prognostic factor for patients with breast cancer. However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to isolate and characterize CTCs in blood sample of a breast cancer patient as a biomarker for monitoring treatments efficacy. In this study, 692 blood samples from 221 breast cancer patients and 376 healthy individuals was used to detect CTCs with multiple markers including epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 19, human epidermal growth factor (HER) 2, Ki67, human telomerase reverse transcriptase (hTERT), and vimentin using quantitative reverse transcription PCR (RT-qPCR). A total of 153 (69.2%) blood samples of 221 patients with breast cancer were found to be positive for at least one of the cancer-associated marker gene before treatment. After chemotherapy, no CTCs were found in 28 (33.3%) of the 84 blood samples analyzed for the presence of CTCs using the RT-qPCR, whereas 56 (66.7%) blood samples were still found to be positive for at least one of the markers. After completing the therapy, the CTC positivity rate decreased to 7 (20.6%) in the neoadjuvant group, whereas this increased to 7 (14%) cases in the adjuvant group. There was no statistically significant relationship between TNM stage and detection of CTC-related markers. Data from this study suggest that RT-qPCR assay for the detection of CTC markers might be useful in selecting appropriate therapeutics and for monitoring treatment efficacy in breast cancer patients.
Full Text
http://www.sciencedirect.com/science/article/pii/S0014480014001440
DOI
10.1016/j.yexmp.2014.09.003
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kim, Seung Il(김승일)
Han, Hyun Ju(한현주)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138625
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links